Modulation of serine/threonine-protein phosphatase 1 (PP1) complexes: a promising approach in cancer treatment
MetadataShow full item record
AbstractCancer is the second leading cause of death worldwide. Despite the numerous therapeutic options available, tumor heterogeneity and chemoresistance have limited their success and the development of an effective anticancer therapy remains a major challenge in oncology research. The serine/threonine-protein phosphatase 1 (PP1) and its complexes have been recognized as potential drug targets. Although research on the modulation of PP1 complexes is currently at an early stage, there is an immense potential. Chemically diverse compounds have been developed to disrupt or stabilize different PP1 complexes in various cancer types with the objective to inhibit disease progression. Beneficial results obtained in vitro now require further pre-clinical and clinical validation. In conclusion, the modulation of PP1 complexes seems to be a promising, albeit challenging, therapeutic strategy for cancer.
CitationMatos, B., Howl, J., Jerónimo, C. and Fardilha, M. (2021) Modulation of serine/threonine-protein phosphatase 1 (PP1) complexes: a promising approach in cancer treatment. Drug Discovery Today, 26(11), pp. 2680-2698. https://doi.org/10.1016/j.drudis.2021.08.001
JournalDrug Discovery Today
DescriptionThis is an accepted manuscript of an article published by Elsevier in Drug Discovery Today, available online at: https://doi.org/10.1016/j.drudis.2021.08.001 The accepted version of the publication may differ from the final published version.
SponsorsPortuguese Foundation for Science and Technology (FCT), European Union, QREN, FEDER and COMPETE funded iBiMED (UID/BIM/04501/2020, POCI-01-0145-FEDER-007628 and UID/BIM/04501/2019) and an individual scholarship from BM (SFRH/BD/146032/2019).
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/